Format

Send to

Choose Destination
Cancer Res. 2015 Oct 15;75(20):4283-91. doi: 10.1158/0008-5472.CAN-15-0471.

Preclinical Validation of the Utility of BLZ-100 in Providing Fluorescence Contrast for Imaging Spontaneous Solid Tumors.

Author information

1
College of Veterinary Medicine, Washington State University, Pullman, Washington.
2
Blaze Bioscience, Inc., Seattle, Washington.
3
PerkinElmer, Inc., Waltham, Massachusetts.
4
Fred Hutchinson Cancer Research Center, Seattle, Washington.
5
Blaze Bioscience, Inc., Seattle, Washington. Julie.novak@blazebioscience.com.

Abstract

There is a need in surgical oncology for contrast agents that can enable real-time intraoperative visualization of solid tumors that can enable complete resections while sparing normal surrounding tissues. The Tumor Paint agent BLZ-100 is a peptide-fluorophore conjugate that can specifically bind solid tumors and fluoresce in the near-infrared range, minimizing light scatter and signal attenuation. In this study, we provide a preclinical proof of concept for use of this imaging contrast agent as administered before surgery to dogs with a variety of naturally occurring spontaneous tumors. Imaging was performed on excised tissues as well as intraoperatively in a subset of cases. Actionable contrast was achieved between tumor tissue and surrounding normal tissues in adenocarcinomas, squamous cell carcinomas, mast cell tumors, and soft tissue sarcomas. Subcutaneous soft tissue sarcomas were labeled with the highest fluorescence intensity and greatest tumor-to-background signal ratio. Our results establish a foundation that rationalizes clinical studies in humans with soft tissue sarcoma, an indication with a notably high unmet need.

PMID:
26471914
PMCID:
PMC4610180
DOI:
10.1158/0008-5472.CAN-15-0471
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center